Core Viewpoint - The flu-related stocks in the A-share market are experiencing significant activity, driven by a surge in demand for flu medications and testing services as the flu season peaks in various regions of China [1] Group 1: Stock Performance - Yue Wannianqing saw a rise of over 16%, while Kangzhi Pharmaceutical increased by over 12%, and Hainan Haiyao and Peking University Pharmaceutical achieved consecutive gains [1] - The stock performance of flu-related companies indicates a strong market response, with notable increases in share prices for several firms [2] Group 2: Market Demand - Demand for flu-related medications and online consultations has surged, particularly in Northeast, North China, and Northwest regions, with Southern cities also experiencing rapid growth [1] - Orders for specific antiviral medications have more than doubled since November, with Mabalosavir tablets increasing by over 110% and Oseltamivir phosphate granules by over 85% compared to the previous month [1] Group 3: Consumer Behavior - Data from Alibaba Health shows a significant increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% increase in the number of buyers for antiviral drugs [1] - Mabalosavir has shown exceptional growth, with a 600% increase in the number of purchasers, indicating heightened consumer awareness regarding flu prevention and treatment [1]

Core Points - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its "Cough Orange Granules" clinical trial [2] Group 1 - The company announced the approval of its clinical trial application for "Cough Orange Granules" [2]

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its product "Cough Orange Granules," which is already in production and sale [2]. Group 1 - The product "Cough Orange Granules" is a national secondary protected traditional Chinese medicine, with its protection period ending on September 13, 2016 [2]. - The current therapeutic functions of the product include "clearing the lungs, relieving cough, and resolving phlegm," specifically for cough with phlegm due to phlegm-heat obstructing the lungs, chest fullness, shortness of breath, and dry throat [2]. - The company has submitted a clinical trial application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing the lungs" based on recent clinical research and expert consensus [2].

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of "Cough Orange Granules" aimed at treating acute exacerbations of chronic obstructive pulmonary disease [1] Group 1 - The company announced the approval of the clinical trial for "Cough Orange Granules" [1] - The clinical trial will focus on patients with acute exacerbations of chronic obstructive pulmonary disease characterized by phlegm heat obstructing the lungs [1] - The company will further refine the clinical trial protocol before proceeding [1]

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its "Cough Orange Granules" to conduct clinical trials for chronic obstructive pulmonary disease during acute exacerbation [1] Group 1 - The company has been granted a "Drug Clinical Trial Approval Notice" for its product [1] - The clinical trial will focus on the application of Cough Orange Granules for acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lung syndrome) [1] - The company is in the process of further refining the clinical trial protocol [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product "Cough Orange Granules," which is already in production and sales [1] Group 1: Product Information - "Cough Orange Granules" is a national secondary protected traditional Chinese medicine with functions for "clearing the lungs, stopping cough, and resolving phlegm" [1] - The product is indicated for cough with phlegm due to phlegm-heat obstructing the lungs, characterized by symptoms such as excessive phlegm, chest fullness, shortness of breath, dry throat, and itching [1] Group 2: Clinical Trial Approval - The company submitted an application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lungs)" and received approval for clinical trials [1] - This approval represents a milestone in the company's drug development efforts [1] Group 3: Financial Impact - The approval of the clinical trial does not have a significant impact on the company's short-term financial status or operating performance [1] - The sales of the product will not be affected by the receipt of the clinical trial approval notification [1]

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of its product "Cough Orange Granules," which is already in production and sales [1] Group 1: Product Information - "Cough Orange Granules" is a product with the approval number Z10980105 and is classified as a national secondary protected traditional Chinese medicine, with its protection period ending on September 13, 2016 [1] - The current indications for the product include "clearing the lungs, stopping cough, and resolving phlegm," specifically for cough with phlegm due to phlegm-heat obstructing the lungs, characterized by excessive phlegm, chest fullness, shortness of breath, and dry throat [1] Group 2: Clinical Trial Approval - The company submitted a clinical trial application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lungs)" based on the latest clinical research and expert consensus [1] - The approval for the clinical trial signifies a potential expansion of the product's therapeutic applications [1]

Core Viewpoint - Kangzhi Pharmaceutical (300086.SZ) has received approval from the National Medical Products Administration for clinical trials of its "Cough Orange Granules" for use in acute exacerbations of chronic obstructive pulmonary disease (COPD) [1] Group 1 - The product "Cough Orange Granules" is already in production and on sale [1] - It was previously classified as a national secondary protected traditional Chinese medicine [1]

证券代码：300086 证券简称：康芝药业 公告编号：2025-057 康芝药业股份有限公司 关于收到止咳橘红颗粒药物临床试验批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，康芝药业股份有限公司（以下简称"公司"）申报的"止咳橘红颗粒" 获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。现将相关情况 公告如下： 一、药物基本情况 1.药品名称：止咳橘红颗粒。 2.注册分类：中药 2.3 类。 3.申请事项目的：增加新功能主治临床试验申请。 4.申请人：康芝药业股份有限公司。 5.审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 09 月 08 日受理的止咳橘红颗粒临床试验申请符合药品注册的有关要求，在进一 步完善临床试验方案的基础上，同意本品开展用于慢性阻塞性肺疾病急性发作期 （痰热壅肺证）的临床试验。 后续公司将根据该产品的研发情况及国家药品注册相关法规的要求，确定药物 临床试验工作。后续临床试验进展具有一定的不确定性，公司将根据该药品的进展 情况及时履行信息披露义务，敬请广大投资者审慎决策，注意投资风险 ...

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]